Abstract
6071 Background: In Italy, the economic burden of chemotherapy-induced nausea and vomiting (CINV) and its impact on a patient's daily life have received little attention. Methods: Prospective observational study in 7 oncology centers. Cancer patients receiving cisplatin-containing regimens reported the incidence and intensity of CINV for 8 consecutive days in a diary and completed a Functional Living Index for Emesis (FLIE) questionnaire. Costs related to emesis (direct medical and non-medical costs and indirect costs, including adverse events) and costs of antiemetic therapy were recorded from the perspectives of the hospital, the patient, and the National Health Service (NHS). Costs from the patient's perspective were obtained using a validated questionnaire. The endpoint “No or minimum Impact on Daily Life” (NIDL) is defined as a total score of 108 FLIE points (average item score >6 on a 7-point scale). Results: 62 of 169 enrolled patients (36.7%) had at least one emetic episode and 102/169 (60.4%) experienced mild nausea. Mean costs per patient of acute and delayed emesis are shown in the table. The impact of CINV on a patient's ability to carry out daily activities was evaluated in 155 patients. Impact on patients' daily life occurred because of nausea (77/155; 49.7%) and vomiting (64/155, 41.3%). Conclusions: 60% of cisplatin-treated patients suffered from nausea and 33% from vomiting. CINV affected patients' daily life in more than 40% of the cases. Costs for prophylaxis and management of emesis are high and variable. The economic burden of CINV and its impact on patients' daily life (especially in the delayed phase) is still considerable despite current antiemetic prophylaxis. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck & Co., Inc. Ballatori Partnership, LLC, Merck & Co., Inc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
